UBS AM’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.4M | Sell |
4,615,516
-1,793,008
| -28% | -$9.07M | ﹤0.01% | 993 |
|
|
2025
Q1 | $33.9M | Buy |
6,408,524
+4,149,346
| +184% | +$22M | 0.01% | 772 |
|
|
2024
Q4 | $15.3M | Buy |
2,259,178
+118,428
| +6% | +$801K | ﹤0.01% | 1062 |
|
|
2024
Q3 | $14.1M | Buy |
2,140,750
+43,078
| +2% | +$284K | ﹤0.01% | 1084 |
|
|
2024
Q2 | $15.7M | Buy |
2,097,672
+1,891,903
| +919% | +$14.2M | ﹤0.01% | 960 |
|
|
2024
Q1 | $2.05M | Sell |
205,769
-21,104
| -9% | -$210K | ﹤0.01% | 1684 |
|
|
2023
Q4 | $2.24M | Buy |
226,873
+15,297
| +7% | +$151K | ﹤0.01% | 1640 |
|
|
2023
Q3 | $1.62M | Buy |
211,576
+96,298
| +84% | +$737K | ﹤0.01% | 1727 |
|
|
2023
Q2 | $769K | Hold |
115,278
| – | – | ﹤0.01% | 2122 |
|
|
2023
Q1 | $769K | Buy |
115,278
+8,347
| +8% | +$55.7K | ﹤0.01% | 2122 |
|
|
2022
Q4 | $824K | Buy |
106,931
+30,052
| +39% | +$232K | ﹤0.01% | 1949 |
|
|
2022
Q3 | $818K | Buy |
76,879
+25,426
| +49% | +$271K | ﹤0.01% | 2086 |
|
|
2022
Q2 | $419K | Buy |
51,453
+3,259
| +7% | +$26.5K | ﹤0.01% | 2364 |
|
|
2022
Q1 | $345K | Buy |
48,194
+12,741
| +36% | +$91.2K | ﹤0.01% | 2563 |
|
|
2021
Q4 | $607K | Buy |
+35,453
| New | +$607K | ﹤0.01% | 2474 |
|